Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2555 - Eribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort


11 Sep 2017


Poster display session




Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


J. MARTIN-BABAU1, M. Robert2, V. Seegers3, M. Paillard4, X. Pivot5, C. Gourmelon2, L. Uwer6, C. Korenbaum7, T. Petit8, J. Thery9, M. Som10, C. Lefeuvre-Plesse10, C. Perret11, H. Simon11, A. Hardy-Bessard1, H. Desclos12, H. Bourgeois13, M. Campone2, O. Tredan14, A. Patsouris15

Author affiliations

  • 1 Medical Oncology, CARIO - Hôpital Privé des Côtes d'Armor, 22190 - Plerin/FR
  • 2 Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 3 Biostatistics, ICO Institut de Cancerologie de l'Ouest Paul Papin, 49100 - Angers/FR
  • 4 Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 5 Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 6 Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 7 Medical Oncology, CHU Hautepierre, 67200 - Strasbourg/FR
  • 8 Medical Oncology, Centre Paul Strauss Centre de Lutte contre le Cancer, 67065 - Strasbourg/FR
  • 9 Medical Oncology, Centre Henri Becquerel, 76000 - Rouen/FR
  • 10 Medical Oncology, Centre Eugène Marquis, 35000 - Rennes/FR
  • 11 Medical Oncology, CHU Brest, 29200 - Brest/FR
  • 12 Medical Oncology, C.H. Broussais, 35400 - St. Malo/FR
  • 13 Medical Oncology, Clinique Victor Hugo Le Mans, 72000 - Le Mans/FR
  • 14 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 15 Medical Oncology, Centre Paul Papin, 49100 - Angers/FR


Abstract 2555


Treating metastatic breast cancer (MBC) in women of 70 years old or more is a frequent problem however few data are available describing the safety and efficacy of chemotherapy in elderly patients. Eribulin is validated for MBC from the 2nd line treatment onwards since two phase III studies. We present here a focus on safety and efficacy of eribulin in patients ≥ 70 years old compared to the results of younger patients in a real life cohort.


From Oct 2014 to Feb 2017, a multicentric retro-prospective study (REPROLINE) was conducted. Data concerning patient, tumor characteristics, previous treatments administered, tolerance, efficacy and outcome of eribulin were retrieved for patients treated in real life for MBC in 12 different French hospitals between Dec 2013 and Jan 2016. Data from 446 MBC patients were collected. This database was splitted in two cohorts: comparing the results from the cohort of 363 patients < 70 years old (group A) to the cohort of 83 patients ≥70 years old or more (group B).


Median age for each cohort was 56.3 and 75.4 years old. Both cohorts had similar tumour characteristics, number of metastatic sites and the median number of prior chemotherapy lines was 2. Albumine serum levels were lower in the group B with 21% of patients with albumine < 30g/L versus 13% in group A, without any statistical difference. Outcomes were similar in group A and B with respectively: median PFS of 3.67 months versus 3.7 months; HR 0.972(CI 95% 0.762-1.241), p = 0.821. median OS 10.7 months vs 10.7 months; HR 0.997 (CI95% 0.752-1.323), p = 0.984. Patients in both groups received a median number of 4 cycles. The most frequent grade 3 adverse events were neutropenia (22.9% in group A and 15.7% in group B), fatigue (6.5% group A and 13.3% group B) and neurotoxicity (4.4% and 3.6%, respectively). No statistical difference between elderly and younger patients was demonstrated. 9.6% of the total patients stopped the treatment due to fatigue.


We present here the first study focusing retro-prospectively on the tolerance and efficacy of eribulin in elderly patients in real life. In this study, eribulin in patients ≥70 years old is as effective and safe as in younger patients.

Clinical trial identification


Legal entity responsible for the study

Anne Patsouris




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.